Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.11 - $9.46 $202,356 - $374,616
39,600 Added 319.35%
52,000 $282,000
Q2 2024

Aug 14, 2024

SELL
$2.87 - $9.1 $9,184 - $29,120
-3,200 Reduced 20.51%
12,400 $59,000
Q1 2024

May 15, 2024

BUY
$2.57 - $4.84 $36,237 - $68,244
14,100 Added 940.0%
15,600 $48,000
Q3 2023

Nov 14, 2023

BUY
$2.75 - $4.48 $1,925 - $3,136
700 Added 87.5%
1,500 $4,000
Q2 2023

Aug 14, 2023

BUY
$2.86 - $4.97 $2,288 - $3,976
800 New
800 $2,000
Q4 2022

Feb 14, 2023

SELL
$2.02 - $3.62 $21,816 - $39,096
-10,800 Reduced 45.96%
12,700 $26,000
Q3 2022

Nov 14, 2022

BUY
$1.22 - $5.14 $10,370 - $43,690
8,500 Added 56.67%
23,500 $77,000

Others Institutions Holding HUMA

About Humacyte, Inc.


  • Ticker HUMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,007,000
  • Market Cap $453M
  • Description
  • Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...
More about HUMA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.